GLP-1 Medication for People Over 65

Yes, people over 65 can be prescribed weight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) in the UK. Neither licence sets an upper age limit for adults, and the product information says no dose change is needed for age alone. But later life brings particular considerations: muscle loss, dehydration, kidney function, falls and the number of other medicines people take. Whether a GLP-1 medicine is right for you is a decision for a prescriber who knows your full health picture. This guide explains what they will weigh up and why.

Why weight and age need a different conversation

Obesity is common in later life, and it contributes to many of the conditions that become more frequent with age: type 2 diabetes, high blood pressure, heart disease, osteoarthritis of the knees and hips, sleep apnoea and some cancers. Reducing excess weight can ease several of these at once. That is part of why interest in GLP-1 medicines among people in their sixties, seventies and beyond has grown.

At the same time, body composition changes as we age. From middle age onwards, people tend to lose muscle mass and strength gradually, a process that can progress to sarcopenia, where low muscle mass and strength begin to affect daily life. Bones also become less dense. Someone in their seventies can carry excess fat while having less muscle than they had at fifty. This combination, sometimes called sarcopenic obesity, means that the quality of any weight loss matters as much as the quantity.

NICE guideline NG246 on overweight and obesity management (2025) emphasises a tailored, person-centred approach rather than a one-size-fits-all target. For older adults, that tends to mean asking what you want to be able to do: walk further, manage stairs, control blood sugar, reduce knee pain or sleep better. Those goals shape whether medication is offered, which one and how it is monitored.

If you are new to the subject, our plain-English explainer on what GLP-1 medications are covers the basics before you read on.

What the licences and product information say about age

The Summaries of Product Characteristics (SmPCs) for Mounjaro and Wegovy, available on medicines.org.uk, are the official documents that set out how these medicines are licensed in the UK. Both state that no dose adjustment is needed based on age. Both are licensed for adults who meet BMI-based criteria alongside a reduced-calorie diet and increased physical activity.

That is not the same as saying the medicines have been studied equally in every age group. Large weight-loss trials such as STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) enrolled adults with an average age in their mid-forties, and included relatively few people in their late seventies or eighties. The SELECT cardiovascular trial of semaglutide recruited people aged 45 and over with established heart disease, so its participants were older on average, in their early sixties. Evidence in very old or frail adults remains more limited, which is one reason prescribers take extra care.

The two tablet options are new in the UK. The MHRA approved oral semaglutide for weight management in June 2026 and Foundayo in August 2026. At the time of writing, real-world experience in older adults is limited, so it is worth checking the current SmPC and asking your prescriber how the evidence applies to you. Our oral GLP-1 guide explains the differences between the tablets.

Potential benefits after 65

Weight-related conditions

The benefits of GLP-1 treatment are not just about weight. In trials, weight loss on these medicines came with improvements in blood pressure, blood sugar and blood fats on average. For an older adult, those changes can be relevant to the conditions most likely to affect quality of life and life expectancy.

• Type 2 diabetes and prediabetes: GLP-1 medicines lower blood glucose. Many people over 65 have type 2 diabetes, and treatment may allow some diabetes medicines to be reduced. See our guide to GLP-1 medication and type 2 diabetes.
• Heart and circulation: the SELECT trial found that semaglutide 2.4mg reduced the risk of major cardiovascular events, such as heart attack and stroke, in people with overweight or obesity and established cardiovascular disease, without diabetes. Wegovy's UK licence reflects a cardiovascular-risk role in some patients.
• Joint pain and mobility: losing excess weight reduces load on weight-bearing joints. Osteoarthritis of the knee is common in later life and weight loss is a recognised part of its management.
• Breathing during sleep: obstructive sleep apnoea becomes more common with age and weight. Tirzepatide was studied specifically in sleep apnoea in the SURMOUNT-OSA trials; our guide to tirzepatide and sleep apnoea covers the details.

Function and independence

For many older people the most important outcome is being able to keep doing things: walking, gardening, travelling, caring for grandchildren or managing at home. Weight loss can help with this if it reduces pain and breathlessness. But it can also undermine it if too much muscle is lost. That tension is the central question in older-adult treatment, and it is covered in detail below.

The specific risks to think about

Muscle and strength

Any approach that produces substantial weight loss, whether medication, very low calorie diets or surgery, leads to some loss of lean mass alongside fat. Lean mass includes muscle, organs and water. Body composition sub-studies of the main GLP-1 trials found that most weight lost was fat, but a meaningful share was lean tissue.

In younger adults with plenty of muscle reserve, this may matter less. After 65, muscle is harder to rebuild, and lower muscle strength is linked to falls, fractures and loss of independence. This is why protein intake and resistance exercise are not optional extras for older adults on GLP-1 treatment. Our guides to preserving muscle on GLP-1 treatment and strength training for beginners give practical detail.

Dehydration and kidney function

Nausea, vomiting and diarrhoea are the most common side effects of GLP-1 medicines, especially when starting and after each dose increase. The SmPCs warn that fluid loss from these effects can lead to dehydration and, in some cases, a deterioration in kidney function.

Older adults are more vulnerable for several reasons. Thirst sensation tends to decline with age. Kidney function often declines gradually too. And many people over 65 take medicines that affect fluid balance or the kidneys, such as diuretics ("water tablets"), ACE inhibitors or angiotensin receptor blockers, and NSAID painkillers. A bout of vomiting on top of these can tip someone into dehydration more quickly than it would a younger person.

Practical steps include drinking regularly through the day, having a plan for what to do if you cannot keep fluids down, and knowing when to seek help. Some prescribers will advise temporarily pausing certain medicines during an episode of vomiting or diarrhoea, sometimes called "sick day rules", but this must come from your own clinician. Our hydration guide covers this in more depth.

Dizziness, low blood pressure and falls

As weight falls, blood pressure often falls too. That is usually welcome, but if you are on blood pressure tablets the combination can cause light-headedness, particularly when standing up quickly. Dehydration makes this worse. For older adults, dizziness raises the risk of falls, which can have serious consequences.

Tell your prescriber if you notice dizziness. Your GP may review your blood pressure medicines as your weight changes. Do not stop or reduce them yourself.

Low blood sugar

GLP-1 medicines on their own rarely cause hypoglycaemia (low blood sugar). The risk rises when they are combined with insulin or sulfonylureas such as gliclazide, which are commonly used in older adults with type 2 diabetes. The SmPCs advise that doses of these medicines may need reducing. Hypoglycaemia in older people can cause confusion and falls and may be less easy to recognise.

Gallbladder and pancreas

Rapid weight loss increases the risk of gallstones, and gallbladder problems are listed as side effects of GLP-1 medicines. Acute pancreatitis is uncommon but serious. Gallstone disease becomes more common with age, so it is worth knowing the warning signs, which are listed in the final section. Our guides to gallbladder problems and pancreatitis risk explain both.

Several medicines at once

Taking five or more regular medicines is common after 65. GLP-1 medicines slow stomach emptying, which can change how some tablets are absorbed. They also interact in practical ways with diabetes medicines, blood pressure tablets and medicines with a narrow safety margin, such as warfarin. Our full guide to GLP-1 medication interactions explains what prescribers look for.

Who might not be suitable

Some reasons to avoid or delay GLP-1 treatment apply at any age, such as a personal or family history of certain thyroid cancers mentioned in the product information, previous pancreatitis, or severe gut conditions such as gastroparesis. Our guide to who should not take GLP-1s lists the contraindications and cautions in detail.

Others are especially relevant in later life:

• Frailty or unintended weight loss. If someone is already losing weight without trying, or is frail, appetite suppression may do more harm than good.
• Low BMI for age or low muscle mass. BMI can underestimate fat and overestimate fitness in older adults, but it can also mislead the other way. A prescriber may look at waist measurement, mobility and strength as well.
• Significant kidney impairment. The SmPCs set out how kidney function affects use. Severe impairment may limit options.
• Cognitive impairment. Weekly injections, recognising side effects and maintaining fluid intake can be harder for someone with memory problems unless there is reliable support.
• Recent or planned surgery. GLP-1 medicines slow stomach emptying, which matters for anaesthesia. See our guide to GLP-1 medication before surgery.
• Eye disease in people with diabetes. Rapid improvement in blood glucose has been associated with a temporary worsening of diabetic retinopathy with semaglutide, so people with existing retinopathy need monitoring.

What a careful assessment looks like

Whether you are seen by your GP, an NHS specialist weight management service or a regulated online provider, an assessment for someone over 65 should cover more than height and weight. You might expect questions or checks on:

Online providers will usually ask for ID and weight verification and may request your GP details so information can be shared. If they do not ask about your other medicines, that is a warning sign. Our guide to the online weight loss consultation explains what a good consultation includes, and our provider comparison sets out how regulated services differ.

Starting and adjusting treatment

Dose increases

Both Mounjaro and Wegovy are started at a low dose and increased gradually, typically every four weeks, to let the body adjust. The schedules are explained in our guides to Mounjaro doses and Wegovy doses.

For older adults, prescribers sometimes stay at a lower dose for longer if side effects are troublesome, or decide that a lower maintenance dose achieves enough benefit. There is no requirement to reach the highest dose. The right dose is the one that balances benefit against side effects for you, and that decision rests with your prescriber.

Practical support

• Injections: both are given with pre-filled pens. If arthritis in the hands or poor eyesight makes this difficult, say so. A family member or carer can be shown how to help.
• Remembering doses: a weekly injection on the same day each week, linked to a routine, helps. The SmPCs give rules for missed doses.
• Eating well with less appetite: smaller, protein-focused meals, not skipping meals, and avoiding very rich or fatty food can reduce nausea. Our guide to what to eat on GLP-1 medication covers this.
• Keeping active: walking plus two or more sessions of strength work each week, adapted to your ability, helps protect muscle and balance.

Monitoring during treatment

Follow-up matters more in later life. Reasonable things to keep an eye on include:

• weight trend, without aiming for very rapid loss
• grip strength, walking speed or how easily you manage stairs and getting up from a chair
• kidney function blood tests, particularly if you have had vomiting or diarrhoea or take medicines that affect the kidneys
• blood pressure and any dizziness
• blood glucose if you have diabetes
• appetite, food intake and signs of under-eating
• mood and energy

If your weight falls faster than expected, or you feel weaker, more tired or unsteady, tell your prescriber. Slowing down, holding the dose or stopping are all reasonable options.

Weight loss goals in later life

Trial averages, such as around 15% weight loss with semaglutide 2.4mg in STEP 1 and around 20% at the highest tirzepatide dose in SURMOUNT-1, describe groups of mostly middle-aged adults over more than a year. Individual results vary widely, and nobody can promise a particular outcome.

For older adults, many clinicians consider more modest weight loss to be both realistic and sufficient, if it improves the health problems that matter. Losing a moderate amount while maintaining or improving strength may be a better outcome than losing a large amount and becoming frailer. Our guide to realistic weight loss expectations discusses this further.

Stopping treatment

Weight regain is common after GLP-1 medicines are stopped, as appetite returns. For older adults this raises a particular concern: if muscle is lost during weight loss and fat is regained afterwards, body composition could end up less favourable than before. This is another reason to protect muscle throughout treatment. Our guide to weight regain after stopping explains the evidence.

NHS and private routes

Age does not exclude you from NHS treatment. Access depends on NICE criteria and local services.

• Wegovy is recommended by NICE (TA875) within specialist weight management services, for a limited period, in people meeting BMI and comorbidity criteria.
• Mounjaro is recommended by NICE (TA1026) and is being introduced in NHS primary care in phases. The first cohort, from June 2025, covers people with the highest clinical need, defined by BMI and the number of weight-related conditions. Older adults are more likely than younger people to have several of these conditions.

Private treatment is available through regulated online pharmacies, online doctor services and clinics. Costs vary and depend on the medicine, the dose and the provider's service model, so we do not quote prices in our guides. See our price comparison for what affects cost. Our guide to private vs NHS weight loss treatment compares the two routes.

If you are treated privately, letting your GP know is particularly important when you are older, because they manage your other medicines and long-term conditions.

For related reading, browse our guides for specific groups, or visit our hubs for weight loss injections and oral GLP-1 tablets.

When to speak to a professional

Talk to your GP, pharmacist or prescriber before starting a GLP-1 medicine if you are over 65, and share a full list of everything you take. During treatment, contact them promptly if you:

• feel dizzy or light-headed, especially on standing, or have a fall
• cannot keep fluids down for more than a day, or pass much less urine than usual
• notice you are eating very little, losing weight faster than expected, or feeling weaker
• have blood sugar readings lower than usual, or symptoms of hypoglycaemia such as shaking, sweating or confusion
• notice changes in your vision if you have diabetes

Seek urgent medical help (call NHS 111, or 999 in an emergency) if you have:

• severe, persistent abdominal pain, which may spread to your back, with or without vomiting (a possible sign of pancreatitis)
• pain in the upper right abdomen with fever or yellowing of the skin or eyes (possible gallbladder problems)
• signs of severe dehydration, such as confusion, extreme drowsiness, very little or no urine, or fainting
• signs of a severe allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing

Any suspected side effect can be reported to the MHRA through the Yellow Card scheme.